Liver transplantation: An update

Netherlands Journal of Medicine

Volumn 65, Issue 10, 2007, Pages 372-380

  Verdonk, R C ^a   van den Berg, A P ^a   Slooff, M J H ^a   Porte, R J ^a   Haagsma, E B ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; APROTININ; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; STEROID; TACROLIMUS; TRANEXAMIC ACID;

AWARENESS; BLEEDING; CARDIOVASCULAR DISEASE; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; LABORATORY TEST; LIFE EXPECTANCY; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; ORGAN DONOR; PATIENT CARE; PATIENT SELECTION; PERIOPERATIVE PERIOD; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SCORING SYSTEM; STANDARDIZATION; SURVIVAL RATE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

HUMANS; IMMUNOSUPPRESSION; LIVER DISEASES; LIVER TRANSPLANTATION; PROGNOSIS; QUALITY OF LIFE; TISSUE DONORS; TRANSPLANTATION;

EID: 36448985675     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963;117:659-76.
2. National Institutes of Health Consensus Development Conference Statement: liver transplantation - June 20-23, 1983. Hepatology 1984;4 (1 suppl):S107-10.
3. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004;10:968-74.
4. Liu JP, Gluud LL, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure. Cochrane Database Syst Rev 2004;(1):CD003628.
5. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64-71.
6. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
7. Collins BH, Pirsch JD, Becker YT, et al. Long-term results of liver transplantation in older patients 60 years of age and older. Transplantation 2000;70:780-3.
8. Herrero JI, Lorenzo M, Quiroga J, et al. De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005;11:89-97.
9. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005;42:799-805.
10. Tatsunami S, Taki M, Shirahata A, Mimaya J, Yamada K. Increasing incidence of critical liver disease among causes of death in Japanese hemophiliacs with HIV-1. Acta Haematol 2004;111:181-4.
11. Castells L, Escartin A, Bilbao I, et al. Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation 2007;83:354-8.
12. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin Liver Dis 2006;26:273-84.
13. Merion RM, Goodrich NP, Feng S. How can we define expanded criteria for liver donors? J Hepatol 2006;45:484-8.
14. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003;9:651-63.
15. Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A. Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation 2003;75:1659-63.
16. Foley DP, Fernandez LA, Leverson G, et al. Donation after cardiac death: the University of Wisconsin experience with liver transplantation. Ann Surg 2005;242:724-31.
17. Maathuis MH, Leuvenink HG, Ploeg RJ. Perspectives in organ preservation. Transplantation 2007 May 27;83(10):1289-98.
18. Cardillo M, De Fazio N, Pedotti P, et al. Split and whole liver transplantation outcomes: a comparative cohort study. Liver Transpl 2006;12:402-10.
19. Yersiz H, Renz JF, Farmer DG, Hisatake GM, McDiarmid SV, Busuttil RW. One hundred in situ split-liver transplantations: a single-center experience. Ann Surg 2003;238:496-505.
20. Burroughs AK, Sabin CA, Rolles K, et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 2006 Jan 21;367(9506):225-32.
21. Ericzon BG, Larsson M, Herlenius G, Wilczek HE. Report from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) and the Domino Liver Transplant Registry (DLTR). Amyloid 2003;10(suppl 1):67-76.
22. Raia S, Nery JR, Mies S. Liver transplantation from live donors. Lancet 1989;2:497.
23. Burra P, Porte RJ. Should donors and recipients be matched in liver transplantation? J Hepatol 2006;45:488-94.
24. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-71.
25. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007;45:797-805.
26. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6.
27. Gayowski T, Marino IR, Singh N, et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 1998;65:499-504.
28. Mor E, Jennings L, Gonwa TA, et al. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obstet 1993;176:219-27.
29. Hendriks HG, van der Meer J, de Wolf JT, et al. Intraoperative blood transfusion requirement is the main determinant of early surgical re-intervention after orthotopic liver transplantation. Transpl Int 2005;17:673-9.
30. de Boer MT, Molenaar IQ, Hendriks HG, Slooff MJ, Porte RJ. Minimizing blood loss in liver transplantaton: progress through research and evolution of techniques. Dig Surg 2005;22:265-75.
31. Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2007;7:185-94.
32. Xia VW, Steadman RH. Antifibrinolytics in orthotopic liver transplantation: current status and controversies. Liver Transpl 2005;11:10-8.
33. Jabbour N, Gagandeep S, Mateo R, Sher L, Genyk Y, Selby R. Transfusion free surgery: single institution experience of 27 consecutive liver transplants in Jehovah's Witnesses. J Am Coll Surg 2005;201:412-7.
34. Polak WG, Miyamoto S, Nemes BA, et al. Sequential and simultaneous revascularization in adult orthotopic piggyback liver transplantation. Liver Transpl 2005;11:934-40.
35. Polak WG, Nemes BA, Miyamoto S, et al. End-to-side caval anastomosis in adult piggyback liver transplantation. Clin Transplant 2006;20:609-16.
36. Jovine E, Mazziotti A, Grazi GL, et al. Piggy-back versus conventional technique in liver transplantation: report of a randomized trial. Transpl Int 1997;10:109-12.
37. Miyamoto S, Polak WG, Geuken E, et al. Liver transplantation with preservation of the inferior vena cava. A comparison of conventional and piggyback techniques in adults. Clin Transplant 2004;18:686-93.
38. Demetris AJ, Ruppert K, Dvorchik I, et al. Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation 2002;74:1290-6.
39. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006;(4):CD005161.
40. Jain A, Demetris AJ, Kashyap R, et al. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001;7:623-30.
41. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006;6:1578-85.
42. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002;360:1119-25.
43. Pageaux GP, Calmus Y, Boillot O, et al. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl 2004;10:1454-60.
44. Ringe B, Braun F, Schutz E, et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001;71:508-15.
45. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7:442-50.
46. Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006;12:1640-8.
47. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001;7:473-84.
48. Semela D, Piguet AC, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007;46:840-8.
49. Zaghla H, Selby RR, Chan LS, et al. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol Ther 2006;23:513-20.
50. Verdonk RC, Buis CI, Porte RJ, Haagsma EB. Biliary complications after liver transplantation: a review. Scand J Gastroenterol Suppl 2006;243;89-101.
51. Noack K, Bronk SF, Kato A, Gores GJ. The greater vulnerability of bile duct cells to reoxygenation injury than to anoxia. Implications for the pathogenesis of biliary strictures after liver transplantation. Transplantation 1993;56:495-500.
52. Morelli J, Mulcahy HE, Willner IR, et al. Endoscopic treatment of post-liver transplantation biliary leaks with stent placement across the leak site. Gastrointest Endosc 2001;54:471-5.
53. Saab S, Martin P, Soliman GY, et al. Endoscopic management of biliary leaks after T-tube removal in liver transplant recipients: nasobiliary drainage versus biliary stenting. Liver Transpl 2000;6:627-32.
54. Verdonk RC, Buis CI, Porte RJ, et al. Anastomotic biliary strictures after liver transplantation: causes and consequences. Liver Transpl 2006;12:726-35.
55. Buis CI, Verdonk RC, van der Jagt EJ, et al. Nonanastomotic biliary strictures after liver transplantation, part 1: Radiological features and risk factors for early vs. Late presentation. Liver Transpl 2007;13:708-18.
56. Buis CI, Hoekstra H, Verdonk RC, Porte RJ. Causes and consequences of ischemic-type biliary lesions after liver transplantation. J Hepatobiliary Pancreat Surg 2006;13:517-24.
57. Guichelaar MM, Benson JT, Malinchoc M, Krom RA, Wiesner RH, Charlton MR. Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am J Transplant 2003;3:885-90.
58. Verdonk RC, Buis CI, van der Jagt EJ, et al. Nonanastomotic biliary strictures after liver transplantation, part 2: Management, outcome, and risk factors for disease progression. Liver Transpl 2007;13:725-32.
59. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001;7:811-5.
60. Zavaglia C, De CL, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005;100:2708-16.
61. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10:534-40.
62. Jacob DA, Neumann UP, Bahra M, et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006;20:211-20.
63. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12:1813-24.
64. Belli LS, Burroughs AK, Burra P, et al. Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study. Liver Transpl 2007;13:733-40.
65. Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006;6:2348-55.
66. Vallejo GH, Romero CJ, de Vicente JC. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol 2005;56:87-99.
67. Haagsma EB, Hagans VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001;34:84-91.
68. Sethi A, Stravitz RT. Review article: medical management of the liver transplant recipient - a primer for non-transplant doctors. Aliment Pharmacol Ther 2007;25:229-45.
69. Munoz SJ, Elgenaidi H. Cardiovascular risk factors after liver transplantation. Liver Transpl 2005;11 (11 suppl 2):S52-6.
70. Neal DA, Tom BD, Luan J, et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation 2004;77:93-9.
71. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002;73:901-6.
72. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40.
73. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003;9:1079-85.
74. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 2006;367:52-6.
75. Buti M, San MR, Brosa M et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005;42:639-45.
76. Haslam DW, James WP. Obesity. Lancet 2005;366:1197-209.